Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 79 recruiting now early-phase tilt #50 of 28,707 conditions

Type 1 Diabetes: early-phase trial registry

79 of 199 indexed Type 1 Diabetes trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #50 of 28,707 conditions by registered trial count.

199 US clinical trials · 79 currently recruiting · #50 of 28,707 conditions by registered trial count

Type 1 Diabetes: 199 US clinical trials tracked, 79 recruiting.

Type 1 Diabetes is the subject of 199 registered US clinical trials on ClinicalTrials.gov, 79 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 16 of these trials.

Enrollment posture brief

Registry condition type-1-diabetes

OPEN 79 | RECR 40% | LATE 21 | EARLY 54 | RANK #50 | SPON 16

Nearest open-share peer: Pregnancy (40% recruiting · 194 trials)

Solid Tumor52.8%Type 1 Diabetes (this)40%Glioblastoma39%Overweight25.3%Rheumatoid Arthritis18.6%
Open-enrollment share among volume-matched conditions near Type 1 Diabetes

Type 1 Diabetes lists 79 open slots (40% of 199 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Type 1 Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Type 1 Diabetes is recruiting above its size-band peers.

    79 of 199 indexed trials (39.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Type 1 Diabetes trials is spread across many organizations.

    University of Colorado, Denver accounts for 16 of 199 trials (8%). 97 distinct sponsors appear on at least one study for this condition label.

  3. Most Type 1 Diabetes trials plan to enrol fewer than 100 people.

    Median target enrolment is 43 among the 199 trials that report a genuine target (sentinel values excluded). 141 of those (70.9%) plan for fewer than 100 participants.

  4. Type 1 Diabetes research is mostly interventional.

    169 interventional and 30 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 130Phase 224Phase 311Phase 410

Open and recent trials

199 total, page 4 of 4

COMPLETED NA 33 participants

The Pediatric Artificial Pancreas Automated Initialization Trial

Marc Breton

NCT06017089

COMPLETED NA 33 participants

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

Massachusetts General Hospital

NCT01684943

COMPLETED NA 33 participants

MyT1DHero: an mHealth Intervention for Type 1 Diabetes

Michigan State University

NCT03521362

COMPLETED NA 32 participants

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

University of Virginia

NCT03174288

COMPLETED NA 30 participants

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

Jaeb Center for Health Research

NCT02137512

COMPLETED NA 30 participants

Context Aware Data Gathering Study

Oregon Health and Science University

NCT04154904

COMPLETED Phase 3 28 participants

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

University of Colorado, Denver

NCT01816165

COMPLETED NA 27 participants

The Monitoring Study

Massachusetts General Hospital

NCT02969863

COMPLETED Phase 1 25 participants

Primary Intervention With Mucosal Insulin

University of Colorado, Denver

NCT02620553

COMPLETED NA 25 participants

Assessment of a Decision Support Tool in Participants With Type 1 Diabetes

Oregon Health and Science University

NCT04428645

COMPLETED NA 25 participants

Two Way Crossover Closed Loop Study MPC vs FMPD

Oregon Health and Science University

NCT04771403

COMPLETED NA 24 participants

The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance

Massachusetts General Hospital

NCT02509065

COMPLETED NA 24 participants

Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes

Yale University

NCT06098729

COMPLETED Phase 4 24 participants

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

Emory University

NCT04157738

COMPLETED Phase 1 24 participants

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

Stanford University

NCT02687256

COMPLETED NA 23 participants

Three-way, Cross-over Closed-loop Exercise Study

Oregon Health and Science University

NCT02241889

COMPLETED Phase 4 21 participants

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Baylor College of Medicine

NCT01718093

COMPLETED NA 21 participants

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

Albert Einstein College of Medicine

NCT00703989

COMPLETED Early Phase 1 20 participants

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

Benaroya Research Institute

NCT05281614

COMPLETED Phase 2 20 participants

An Outpatient Pump Shutoff Pilot Feasibility and Safety Study

Jaeb Center for Health Research

NCT01736930

COMPLETED Phase 3 20 participants

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

Baylor College of Medicine

NCT00206297

COMPLETED NA 18 participants

Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus

University of Virginia

NCT04439903

COMPLETED Phase 1 17 participants

Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

Yale University

NCT01855490

COMPLETED 16 participants

Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder

HealthPartners Institute

NCT00818142

COMPLETED Phase 1 16 participants

Evaluating the Benefits of Physiologic Insulin Delivery

Stanford University

NCT04416737

COMPLETED NA 15 participants

Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery

Marc Breton

NCT05528770

COMPLETED Phase 1 15 participants

Cord Blood Plus Vitamin D and Omega 3s in T1D

University of Florida

NCT00873925

COMPLETED NA 14 participants

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

Sansum Diabetes Research Institute

NCT04142229

COMPLETED Phase 2 14 participants

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Legacy Health System

NCT00797823

COMPLETED Phase 1 14 participants

Islet Transplantation in Type 1 Diabetic Patients

University of Wisconsin, Madison

NCT00214253

COMPLETED NA 13 participants

Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes

NYU Langone Health

NCT03020069

COMPLETED Early Phase 1 13 participants

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

Yale University

NCT01945099

COMPLETED Phase 1 12 participants

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

Indiana University

NCT04114357

COMPLETED Phase 1 12 participants

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

University of California, San Diego

NCT04545411

COMPLETED NA 12 participants

Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)

University of Virginia

NCT00977808

COMPLETED 12 participants

Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control

Sansum Diabetes Research Institute

NCT02190669

COMPLETED Phase 2 10 participants

Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla

University of Minnesota

NCT00786825

COMPLETED NA 10 participants

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Yale University

NCT02673138

COMPLETED Phase 1 10 participants

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

University of Pittsburgh

NCT00445913

COMPLETED NA 10 participants

Pramlintide in Adolescents With Type 1 Diabetes

University of Colorado, Denver

NCT00842075

COMPLETED Phase 2 10 participants

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

University of Colorado, Denver

NCT03878277

COMPLETED NA 10 participants

Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

University of Pennsylvania

NCT03215914

COMPLETED Phase 2 9 participants

Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes

Massachusetts General Hospital

NCT01527981

COMPLETED NA 8 participants

Safety and Feasibility of a Low Carbohydrate Diet in Children With Type 1 Diabetes

Washington University School of Medicine

NCT04228822

COMPLETED Phase 2 8 participants

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

University of Michigan

NCT01480297

COMPLETED NA 7 participants

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

Capillary Biomedical

NCT04398030

COMPLETED Phase 1 6 participants

hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

University of Minnesota

NCT00285194

COMPLETED Phase 3 5 participants

Liraglutide in Adolescents With Type 1 Diabetes

University at Buffalo

NCT02516657

COMPLETED Early Phase 1 3 participants

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

Yale University

NCT03666065

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 30
Phase 2 24
Phase 3 11
Phase 4 10

Named interventions

Most-linked intervention names on Type 1 Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
18 trials
Placebo Other
8 trials
Diabetes Education Behavioral
3 trials
Insulin Degludec Drug
2 trials
Diabetes Body Project Behavioral
2 trials
Digital resources for diabetes Behavioral
2 trials
FAMS-T1D Behavioral
2 trials
REMD-477 Drug
2 trials

US sites by state

Facility locations filed on Type 1 Diabetes trials. A trial with sites in several states counts in each.

California 48 trials
Colorado 37 trials
Massachusetts 25 trials
Virginia 21 trials
Florida 21 trials
Minnesota 18 trials
Connecticut 16 trials
New York 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Type 1 Diabetes page

199 registered trials, 79 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 1 Diabetes condition card totals 199 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.